Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Author: Blake, S.
Hughes, T.
Mayrhofer, G.
Lyons, A.
Citation: Clinical Immunology, 2008; 127(3):330-339
Publisher: Academic Press Inc
Issue Date: 2008
ISSN: 1521-6616
Statement of
Stephen Blake, Timothy P. Hughes, Graham Mayrhofer and A. Bruce Lyons
Abstract: Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib. Dasatinib also inhibits many Src-family tyrosine kinases. We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clinically relevant concentrations. T-cell functions including proliferation, activation and cytokine production were all uniformly inhibited in the presence of dasatinib. We also demonstrated inhibition of TCR signalling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signalling by dasatinib is responsible for the suppression of T-cell function. These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.
Keywords: T-cells
Immune suppression
Signal transduction
Description: Copyright © 2008 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.clim.2008.02.006
Appears in Collections:Aurora harvest 5
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.